WO2004019864A3 - Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample - Google Patents

Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample Download PDF

Info

Publication number
WO2004019864A3
WO2004019864A3 PCT/US2003/026169 US0326169W WO2004019864A3 WO 2004019864 A3 WO2004019864 A3 WO 2004019864A3 US 0326169 W US0326169 W US 0326169W WO 2004019864 A3 WO2004019864 A3 WO 2004019864A3
Authority
WO
WIPO (PCT)
Prior art keywords
pcr
quantitative
cell sample
angiogenic activity
diagnose cancer
Prior art date
Application number
PCT/US2003/026169
Other languages
French (fr)
Other versions
WO2004019864A2 (en
Inventor
Edward H Lin
Xifeng Wu
Keping Xie
Original Assignee
Univ Texas
Edward H Lin
Xifeng Wu
Keping Xie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Edward H Lin, Xifeng Wu, Keping Xie filed Critical Univ Texas
Priority to JP2004532937A priority Critical patent/JP2005537012A/en
Priority to EP03791717A priority patent/EP1543141A4/en
Priority to NZ538451A priority patent/NZ538451A/en
Priority to CA002496003A priority patent/CA2496003A1/en
Priority to AU2003265555A priority patent/AU2003265555A1/en
Publication of WO2004019864A2 publication Critical patent/WO2004019864A2/en
Publication of WO2004019864A3 publication Critical patent/WO2004019864A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Abstract

The present invention involves the use of quantitative RT-PCR to identify AC133 as a marker. AC133 is prevalent on endothelial progenitor cells (EPCs), which are important cells in angiogenesis. Therefore, the invention is applied to ascertain the quantity of EPCs in a subject, and to diagnose and monitor angiogenesis, for example, in injured tissues and in cancer development and progression.
PCT/US2003/026169 2002-08-28 2003-08-21 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample WO2004019864A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004532937A JP2005537012A (en) 2002-08-28 2003-08-21 Quantitative RT-PCR for AC133 for cancer diagnosis and monitoring of angiogenic activity in cell samples
EP03791717A EP1543141A4 (en) 2002-08-28 2003-08-21 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample
NZ538451A NZ538451A (en) 2002-08-28 2003-08-21 Single-step, highly sensitive yet specific and quantitative method to detect and quantify endothelial progenitor cells (EPCs) in human peripheral blood
CA002496003A CA2496003A1 (en) 2002-08-28 2003-08-21 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample
AU2003265555A AU2003265555A1 (en) 2002-08-28 2003-08-21 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40653502P 2002-08-28 2002-08-28
US60/406,535 2002-08-28
US10/618,102 2003-07-11
US10/618,102 US7252976B2 (en) 2002-08-28 2003-07-11 Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample

Publications (2)

Publication Number Publication Date
WO2004019864A2 WO2004019864A2 (en) 2004-03-11
WO2004019864A3 true WO2004019864A3 (en) 2004-08-05

Family

ID=31981413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026169 WO2004019864A2 (en) 2002-08-28 2003-08-21 Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample

Country Status (8)

Country Link
US (1) US7252976B2 (en)
EP (1) EP1543141A4 (en)
JP (1) JP2005537012A (en)
KR (1) KR20050034749A (en)
AU (1) AU2003265555A1 (en)
CA (1) CA2496003A1 (en)
NZ (1) NZ538451A (en)
WO (1) WO2004019864A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077578A1 (en) * 2004-03-02 2007-04-05 Primagen Holding B.V. Diagnosis of (a risk of ) disease and monitoring of therapy
EP1571225A1 (en) * 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
JP4834553B2 (en) * 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CA2620594C (en) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition having improved disintegratability
CN101316590B (en) 2005-11-07 2011-08-03 卫材R&D管理有限公司 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US20100040637A1 (en) * 2005-11-23 2010-02-18 Karen Van Orden Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133)
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
KR101472600B1 (en) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) * 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
NZ581742A (en) 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
JP5391400B2 (en) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 Method for assisting detection of pancreatic cancer using copy number or expression level of α-actinin-4 gene as an index and kit for diagnosis
AU2008325608B2 (en) * 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA3069077C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010088230A2 (en) * 2009-01-30 2010-08-05 Kci Licensing, Inc. Adult stem cell assays
WO2010123626A1 (en) * 2009-04-24 2010-10-28 University Of Southern California Cd133 polymorphisms and expression predict clinical outcome in patients with cancer
MX2012014776A (en) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Antitumor agent using compounds having kinase inhibitory effect in combination.
RU2580609C2 (en) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer therapeutic agent
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
MX2015004979A (en) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Amorphous form of quinoline derivative, and method for producing same.
WO2014124174A2 (en) * 2013-02-08 2014-08-14 Children's Hospital Los Angeles Circulating bmec and related cells as biomarkers of cns diseases associated with the blood-brain-barrier disorders
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3524595T3 (en) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CN107428818A (en) 2015-01-29 2017-12-01 密西根州立大学校董会 Hide polypeptide and application thereof
MX2017010474A (en) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative.
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
MX2017015896A (en) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Anticancer agent.
AU2019211446A1 (en) 2018-01-25 2020-09-10 Biogen Ma Inc. Methods of treating spinal muscular atrophy
MA52655A (en) 2018-03-30 2021-02-17 Incyte Corp BIOMARKERS FOR INFLAMMATORY SKIN DISEASE
US20210349097A1 (en) 2018-10-05 2021-11-11 Eisai R&D Management Co., Ltd. Biomarkers for a combination therapy comprising lenvatinib and everolimus
EP3861346A1 (en) 2018-10-05 2021-08-11 Eisai R&D Management Co., Ltd. Biomarkers for a therapy comprising a sorafenib compound
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy
CN114040764A (en) 2019-02-15 2022-02-11 因赛特公司 Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
MX2022001940A (en) 2019-08-14 2022-05-10 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors.
PE20221905A1 (en) 2019-10-11 2022-12-23 Incyte Corp BICYCLIC AMINES AS INHIBITORS OF CDK2
EP4204546A1 (en) 2020-08-31 2023-07-05 City of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
WO2023172921A1 (en) 2022-03-07 2023-09-14 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041224A1 (en) * 1996-04-26 1997-11-06 Amcell Corporation Human hematopoietic stem and progenitor cell antigen and methods for its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776154A (en) 1996-02-20 1998-07-07 Cardiothoracic Systems, Inc. Surgical instruments for making precise incisions in a cardiac vessel
PT938320E (en) 1996-03-26 2010-09-22 Michael S Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US6037129A (en) 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
JP2004510951A (en) 1999-03-15 2004-04-08 イオス　バイオテクノロジー，インコーポレイティド Novel methods, compositions, and screening methods for modulating colorectal cancer
US20020076707A1 (en) 2000-06-30 2002-06-20 David Mack Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041224A1 (en) * 1996-04-26 1997-11-06 Amcell Corporation Human hematopoietic stem and progenitor cell antigen and methods for its use
US6455678B1 (en) * 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATHIA M.: "AC133 expression in human stem cells", LEUKEMIA, vol. 15, no. 11, 2001, pages 1685 - 1688, XP003007971 *
YIN ET AL.: "AC133, a novel marker for human hematopoietic stem and progenitor cells", BLOOD, vol. 12, no. 90, December 1997 (1997-12-01), pages 5002 - 5012, XP002264586 *

Also Published As

Publication number Publication date
US20040086915A1 (en) 2004-05-06
NZ538451A (en) 2009-04-30
EP1543141A4 (en) 2006-10-11
WO2004019864A2 (en) 2004-03-11
KR20050034749A (en) 2005-04-14
CA2496003A1 (en) 2004-03-11
US7252976B2 (en) 2007-08-07
JP2005537012A (en) 2005-12-08
AU2003265555A1 (en) 2004-03-19
EP1543141A2 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
WO2004019864A3 (en) Quantitative rt-pcr to ac133 to diagnose cancer and monitor angiogenic activity in a cell sample
WO2007028070A3 (en) Use of soluble flt-1 and its fragments in cardiovascular conditions
MXPA03004105A (en) Making a prognosis in cases of cardiac disease using a combination of markers.
TW200745543A (en) System and methods for providing corrected analyte concentration measurements
WO2006009860A3 (en) Methods for identifying stem cells based on nuclear morphotypes
MXPA05010385A (en) A method and kit for detecting the early onset of renal tubular cell injury.
WO2008014132A3 (en) Combination analyte measurement device and method of use
EP1279033A4 (en) Electrochemical biosensor test strip with recognition electrode and readout meter using this test strip
GB2426064A (en) Disposable blood test device
WO2006024466A3 (en) Test device for the in vitro diagnosis of multi-analyte tests and the use thereof
WO2008007277A3 (en) Detection of analytes in a dual-mediator electrochemical test strip
WO2000062070A3 (en) Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
WO2009048681A3 (en) Methods of tissue-based diagnosis
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
WO2005089310A3 (en) Breath test for oral malodor
WO2006084299A3 (en) Method for evaluating the allergen sensitivity of an individual
WO2006091403A3 (en) Systemic markers for asthma and analogous diseases
WO2001055719A3 (en) Diagnostic kit for detecting creatine levels
EP1825261A4 (en) Diagnosis of conditions associated with decreased arginine bioavailability
WO2008067806A3 (en) Diagnosis and risk stratification of cardiac insufficiency using neurophysin
TW200730136A (en) Dual transdermal analyte sensor assembly and methods of using the same
WO2008055225A3 (en) Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
WO2006055422A3 (en) Sampling device and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 166880

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2496003

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003265555

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 538451

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020057003352

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004532937

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003791717

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057003352

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038245817

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003791717

Country of ref document: EP